Equillium secures $35 million PIPE financing from RA Capital for inflammatory disease programme

Equillium has raised $35 million through a private investment from RA Capital Management to advance clinical development of EQ504, an oral therapy for ulcerative colitis. The funding extends the company's operational runway into 2029 as it progresses the selective aryl hydrocarbon receptor modulator through clinical trials.

Equillium has entered into a securities purchase agreement with RA Capital Management for a private investment in public equity (PIPE) financing expected to yield approximately $35 million in gross proceeds, according to an official announcement. The transaction involves the issuance of approximately 18.9 million shares of common stock and pre-funded warrants at a purchase price of $1.854 per share, representing the five-day average closing price prior to the financing.

Equillium is a clinical-stage biotechnology company developing therapies for severe autoimmune and inflammatory disorders. RA Capital Management is a healthcare-focused investment firm specialising in public and private equity investments in life sciences companies. The proceeds will support continued clinical development of EQ504, an investigational oral aryl hydrocarbon receptor modulator designed to target the colon locally for ulcerative colitis treatment. The company positions EQ504 as a potential standalone or combination therapy addressing inflammatory bowel disease. Funds will also be allocated to working capital and general corporate purposes, with CEO Bruce Steel stating the financing is expected to sustain operations into 2029. This development matters for the inflammatory disease therapeutics sector, where oral gut-targeted mechanisms represent a competitive frontier in ulcerative colitis treatment.

RA Capital's participation signals institutional confidence in EQ504's differentiation within a crowded inflammatory bowel disease pipeline that includes JAK inhibitors, S1P receptor modulators, and advanced biologics. For biotechnology investors, the financing structure avoids public market volatility while providing non-dilutive registration rights for future resale. The transaction highlights continued appetite for specialised autoimmune assets despite challenging biotech funding environments. Clinical-stage companies with focused programmes and institutional backing may find similar PIPE structures accessible for extending development timelines.